查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595651

干癣药物市场：按分子、给药途径、剂型和作用机制分类 - 2025-2030 年全球预测

Psoriasis Therapeutics Market by Molecule (Biologics, Small Molecules), Route of Administration (Oral, Parenteral, Topical), Dosage Forms, Mechanism of Action - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年干癣治疗市场价值为216.2亿美元，预计到2024年将达到237.1亿美元，复合年增长率为9.77%，到2030年将达到415.5亿美元。

干癣药物市场包括多种旨在缓解牛皮癣症状的治疗方法，干癣是一种慢性自体免疫皮肤病，其特征为红色鳞状斑块。治疗方案着重于控制发炎和皮肤细胞增殖，包括局部用药、照光治疗和全身给药的药物，例如针对特定免疫途径的生物製药。开发干癣药物的必要性源于该疾病对患者生活品质的影响以及常规治疗方法的功效和安全性有限。这些治疗剂应用于各种环境，包括医院、专科诊所和居家医疗，以解决医疗保健相关的品质改进和经济负担问题。干癣患病率的增加、意识的提高和生物技术的进步推动了市场的扩张。主要影响因素包括患者对有效治疗的需求增加、新药核准以及生技药品和小分子技术的进步。一个值得注意的机会是个人化医疗的发展，特别是客製化生技药品，以促进更有效的患者治疗结果。市场参与者也正在探索小分子抑制剂和基因治疗等新的治疗领域，这些领域具有巨大的成长潜力。

主要市场统计
基准年[2023] 216.2亿美元
预测年份 [2024] 237.1亿美元
预测年份 [2030] 415.5亿美元
复合年增长率（%） 9.77%

相反，高昂的治疗成本、严格的监管流程以及长期使用某些治疗方法的副作用等挑战正在阻碍成长。由于干癣的慢性性质，患者用药依从性可能会使市场状况更加复杂。创新治疗方法将探索具有更高疗效和安全性的新型生物製药、用于远距患者管理的远端医疗，以及使用人工智慧对患者进行分层和改进治疗方法。虽然市场表现出动态和包容性，但持续投资研究和克服挑战对于永续成长至关重要。鼓励公司优先考虑策略伙伴关係关係，扩大研发线产品，并参与全面的数位行销宣传活动，以抓住新的市场机会。

市场动态：揭示快速发展的干癣药物市场的关键市场洞察

供需的动态交互作用正在改变干癣药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 世界老年人口的增加
    • 斑块型干癣和干癣干癣的盛行率增加
    • 此类治疗的优惠报销政策
  • 市场限制因素
    • 治疗药物高成本
  • 市场机会
    • 处方量和生物製药核准的增加
    • 新生技药品和新管线药物的开发
  • 市场挑战
    • 药物可能带来的健康风险

波特的五力：驾驭干癣药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对干癣药物市场的影响

外部宏观环境因素在塑造干癣治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解干癣治疗药物市场的竞争状况

对干癣治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵干癣治疗市场供应商的绩效评估

FPNV 定位矩阵是评估干癣治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为干癣治疗药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对干癣治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的老年人口正在增加
      • 斑块型干癣和干癣性关节炎的发生率增加
      • 此类疗法的优惠报销政策
    • 抑制因素
      • 治疗费用上涨
    • 机会
      • 生物製药的处方和核准数量增加
      • 新生技药品和新管线药物的新进展
    • 任务
      • 药物可能带来的健康风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以分子分類的干癣治疗药物市场

  • 生物製药
  • 小分子

第七章干癣治疗药物市场：依给药途径

  • 口服
  • 胃肠外的
  • 话题

第八章按剂型分類的干癣治疗药物市场

  • 液体
  • 半固体
  • 固体的

第九章干癣治疗药物市场（依作用机转）

  • IL阻断剂
  • PDE4抑制剂
  • 肿瘤坏死因子抑制剂

第十章北美和南美干癣药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区干癣药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的干癣药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson services, inc
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-035AB9C0DA46

The Psoriasis Therapeutics Market was valued at USD 21.62 billion in 2023, expected to reach USD 23.71 billion in 2024, and is projected to grow at a CAGR of 9.77%, to USD 41.55 billion by 2030.

The psoriasis therapeutics market encompasses a range of medical treatments designed to alleviate the symptoms of psoriasis, a chronic autoimmune skin disease characterized by red, scaly patches. With a focus on managing inflammation and skin cell proliferation, treatment options include topical agents, phototherapy, and systemic medications like biologics targeting specific immune pathways. The necessity of advancing psoriasis therapeutics stems from the disease's impact on patients' quality of life and the limited efficacy and safety of traditional treatments. These therapeutics are applied across diverse settings, including hospitals, specialty clinics, and home care, addressing both health-related quality improvement and economic burden concerns. The market's expansion is propelled by an increasing prevalence of psoriasis, growing awareness, and advancements in biotechnology. Key influencing factors include rising patient demand for efficient treatments, new drug approvals, and technological advancements in biologics and small molecules. One notable opportunity lies in personalized medicine, particularly the development of tailor-made biologics, fostering more effective patient outcomes. Market players are also exploring new therapy areas, such as small-molecule inhibitors and gene therapies, which underline significant growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 21.62 billion
Estimated Year [2024] USD 23.71 billion
Forecast Year [2030] USD 41.55 billion
CAGR (%) 9.77%

Conversely, growth is hampered by challenges such as high treatment costs, stringent regulatory processes, and side-effects associated with long-term use of certain therapies. Patient adherence may further complicate the market landscape due to the chronic nature of psoriasis. Innovation lies in researching novel biologic agents with enhanced efficacy and safety profiles, exploring telemedicine for remote patient management, and leveraging AI for improved patient stratification and treatment regimens. The market shows a dynamic and receptive nature, yet continuous investment in research and overcoming these challenges will be vital for sustained growth. Businesses are recommended to prioritize strategic partnerships, expand pipeline products, and engage in comprehensive digital marketing campaigns to capture emerging market opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Therapeutics Market

The Psoriasis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing elderly population worldwide
    • Increasing incidence of plaque psoriasis and psoriasis arthritis
    • Favorable reimbursement policies for such therapeutics
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Rising prescription volume and approvals of biologic products
    • Emerging development of new biologics and novel pipeline drugs
  • Market Challenges
    • Probable health risks due to the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Therapeutics Market

A detailed market share analysis in the Psoriasis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Therapeutics Market

A strategic analysis of the Psoriasis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson services, inc, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer Inc, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule, market is studied across Biologics and Small Molecules.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Dosage Forms, market is studied across Liquid, Semi-Solid, and Solid.
  • Based on Mechanism of Action, market is studied across IL Blocker, PDE4 Inhibitors, and TNF Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population worldwide
      • 5.1.1.2. Increasing incidence of plaque psoriasis and psoriasis arthritis
      • 5.1.1.3. Favorable reimbursement policies for such therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising prescription volume and approvals of biologic products
      • 5.1.3.2. Emerging development of new biologics and novel pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Probable health risks due to the medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Psoriasis Therapeutics Market, by Molecule

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Psoriasis Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Psoriasis Therapeutics Market, by Dosage Forms

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Semi-Solid
  • 8.4. Solid

9. Psoriasis Therapeutics Market, by Mechanism of Action

  • 9.1. Introduction
  • 9.2. IL Blocker
  • 9.3. PDE4 Inhibitors
  • 9.4. TNF Inhibitors

10. Americas Psoriasis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Psoriasis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Psoriasis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca Plc
  • 5. Bausch Health Companies Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline plc
  • 10. Johnson & Johnson services, inc
  • 11. LEO Pharma A/S
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. PSORIASIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PSORIASIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PSORIASIS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023